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Glioma is a lethal brain cancer, and current treatment strategies have
limited effects by extending life only by a few months. Thus, efforts
should be made to discover better inhibitors of glioma growth. Ideally
such inhibitors will suppress the progression of glioma by (a) inhibiting
the underlying molecular pathways activated in glioma, or (b) prevent
rapid proliferation of the glia and other cells that encompass the glioma
tumor. We have developed a glioma model by co-activating PI3K and
Ras/MAPK specifically in the Drosophila CNS glia. The Drosophila
glioma cause the larval brain to appear enlarged due to rapid increase in
the stem cells and their glial and neural progeny. These tumors cause
the larvae to enter a prolonged larval phase, and eventually kill the
organism. We are conducting a chemical screen using Tyrosine kinase
inhibitors (Selleck Biochem.) in which we feed early third instar (72h old)
larvae 10 or 300uM chemicals in DMSO and then see effects on glioma
growth, and survival in mature third instar stage (120h old). Using these
metrics, here we present data from our screen on B1-B11 of the library.
Once we identify potential glioma inhibitors in the primary screens, we
will validate them in secondary screens.
Abstract
Introduction
Goal of research is to conduct a chemical screen in which a
drug that inhibits glioma growth by either (a) inhibiting the
underlying molecular pathways activated in glioma, or (b)
prevent rapid proliferation of the glia and other cells that
encompass the glioma tumor, is identified.The research is
conducted using Drosophila melanogaster, which is a good
model for not only its relatively small size (around 3mm long)
and high reproduction rated, but also the fact that at least 75%
of genes that cause disease in humans are also found in
Drosophila.
To set up the drug screen, the glioma will be induced in the
F1 larvae using GAL4-UAS approach from a cross between
repoGAL4 X UASPtenRNAi; UASRasV12. These glioma models
will then be tested with known Tyrosine kinase inhibitors from
the same chemical library at both 10µM and 300µM to start.
Data of drugs from classes D and G is collected through
imaging of the larvae Drosophila brain at Days 5 and 6, and the
size of the pupae brain at Day 7. These images will be
analyzed to determine any change in growth of the tumor, and if
change is detected the specific drug will be looked at
independently.
Future Directions
We will continue to test different types of drugs to see if 
there are any potential glioma inhibitors. Once an inhibitor is 
found, we will do a secondary screen. After this trial, more 
specific tests will be performed. For example, isolating the 
glioma to a specific part of the brain and testing effects of 
potential enhancers and suppressors.
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Conclusions
❑ Our studies showed that these drugs, when 
compared to the control, either enhanced the size of 
the glioma in the Drosophila Melanogaster or stayed 
approximately the same size. The class D drugs had 
a larger enhancement than the class G, but overall 
the brain was also enlarged when compared to the 
control meaning that it can be ruled out for future 
studies.
❑ We tested the drug using 10µM and 300 µM with 
drugs D1, G6, D2, G10, and G9 from the tyrosine 
kinase inhibitor drug library
❑ It’s also to be noted that the GFP expression stayed 
the same for the Drosophila Melanogaster Larvae 




Step 1: Allow the two stock types 
to breed
PteniV12 Repo
Step 3: Wait 3 days for the new 
larvae to form
Step 2: Combine the Pteniv12 virgin 
♀ and Repo ♂
Non-TM6B
Step 6: Observe vials and 
record/analyze data
Step 4: Larvae are treated with 
drugs in vials
Step 5: On the 5th & 6th day, the 
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